Satellos Bioscience Inc. (MSCL.TO)

CAD 0.64

(1.59%)

Total Liabilities Summary of Satellos Bioscience Inc.

  • Satellos Bioscience Inc.'s latest annual total liabilities in 2023 was 3.62 Million CAD , up 28.06% from previous year.
  • Satellos Bioscience Inc.'s latest quarterly total liabilities in 2024 Q1 was 3.75 Million CAD , up 3.59% from previous quarter.
  • Satellos Bioscience Inc. reported annual total liabilities of 2.83 Million CAD in 2022, up 34.51% from previous year.
  • Satellos Bioscience Inc. reported annual total liabilities of 2.1 Million CAD in 2021, up 60.21% from previous year.
  • Satellos Bioscience Inc. reported quarterly total liabilities of 3.75 Million CAD for 2024 Q1, up 3.59% from previous quarter.
  • Satellos Bioscience Inc. reported quarterly total liabilities of 3.62 Million CAD for 2023 FY, up 28.06% from previous quarter.

Annual Total Liabilities Chart of Satellos Bioscience Inc. (2023 - 2019)

Historical Annual Total Liabilities of Satellos Bioscience Inc. (2023 - 2019)

Year Total Liabilities Total Liabilities Growth
2023 3.62 Million CAD 28.06%
2022 2.83 Million CAD 34.51%
2021 2.1 Million CAD 60.21%
2020 1.31 Million CAD 97.54%
2019 664.81 Thousand CAD 0.0%

Peer Total Liabilities Comparison of Satellos Bioscience Inc.

Name Total Liabilities Total Liabilities Difference
Appili Therapeutics Inc. 12.41 Million CAD 70.81%
Eupraxia Pharmaceuticals Inc. 25.54 Million CAD 85.814%
Helix BioPharma Corp. 1.57 Million CAD -129.512%
Microbix Biosystems Inc. 11.02 Million CAD 67.14%
Medicenna Therapeutics Corp. 13.94 Million CAD 74.008%
Oncolytics Biotech Inc. 11.25 Million CAD 67.807%
Sernova Corp. 9.59 Million CAD 62.22%